Mupirocin 2% · topical cream
Antibiotic
Approved uses
Secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible isolates of S. aureus and S. pyogenes
A small amount applied with a cotton swab or gauze to the affected area three times daily for 10 days
The label explicitly says not for ophthalmic use: this is a skin preparation, not a lid-margin or ocular one
Contraindications
Mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream.
Mupirocin cream 2%, in 15 g and 30 g tubes.
Mupirocin is an RNA synthetase inhibitor antibacterial.
Warnings & Precautions
- Severe Allergic Reactions: Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash, have been reported in patients treated with formulations of mupirocin, including mupirocin cream.
- Eye Irritation: Avoid contact with the eyes. In case of accidental contact, rinse well with water.
- Local Irritation: In the event of a sensitization or severe local irritation from mupirocin cream, usage should be discontinued, and appropriate alternative therapy for the infection instituted.
- Clostridium difficile-Associated Diarrhea: CDAD has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use, and has been reported to occur over 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.
- Potential for Microbial Overgrowth: Prolonged use of mupirocin cream may result in overgrowth of nonsusceptible microorganisms, including fungi.
- Risk Associated with Mucosal Use: Mupirocin cream is not formulated for use on mucosal surfaces. It is not for intranasal, ophthalmic, or other mucosal use.
Common Side Effects
The most frequent adverse reactions (at least 1%) were headache, rash, and nausea.
Pregnancy: There are insufficient human data to establish whether there is a drug-associated risk with mupirocin cream in pregnant women. Systemic absorption of mupirocin through intact human skin is minimal following topical administration.
Lactation: It is not known whether mupirocin is present in human milk, has effects on the breastfed child, or has effects on milk production. Breastfeeding is not expected to result in exposure of the child to the drug due to the minimal systemic absorption of mupirocin. A breast and/or nipple being treated with mupirocin cream should be thoroughly washed prior to breastfeeding.
The safety and effectiveness of mupirocin cream have been established in the age-groups 3 months to 16 years. Use of mupirocin cream in these age-groups is supported by evidence from adequate and well‑controlled trials of mupirocin cream in adults with additional data from 93 pediatric subjects studied as part of the pivotal trials in adults.